Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,230.71
(
-0.16%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
78,051.27
(
0.55%
)
News Focus
News Focus
Post# of 822893
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

HyGro

Send PM Follow Ignore
Followers 24
Posts 4176
Boards Moderated 0
Alias Born 12/18/2019

HyGro

Re: Extremist223 post# 499779

Monday, 08/01/2022 1:52:21 PM

Monday, August 01, 2022 1:52:21 PM

Post# of 822893
Methylated Tumors were not an endpoint of the NWBO P3 trial. Hard to get any approval if you a.) don't design the trial for the proper data for approval, and then, b.) don't have a treatment and comparator arm to read the effect.

So how would it get approved?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News